Exploring New Frontiers in low Testosterone Treatment
Centennial, Colorado, March 20, 2025 (GLOBE NEWSWIRE) -- Acesis BioMed, a biomedical company is proud to announce the launch of its crowdfunding campaign. This initiative aims to propel the development of its innovative pipeline of candidate drugs, patented oral treatments designed to stimulate the body's own production of natural testosterone (T). Untreated low T is linked to serious health problems - it can lead to metabolic disorders, cardiovascular disease risk, and reduced quality of life.
The funds raised through this campaign will play a pivotal role in accelerating the transition of our drug candidate pipeline from preclinical toward a Phase I clinical trial. By participating in this effort, investors may contribute to an innovative solution in men's well being and help address a global health concern. With a growing market for testosterone-related therapies, projected to reach $2.53 billion by 2029, Acesis's drug pipeline has the potential to redefine how testosterone deficiency and diseases in which T plays a role (obesity, type 2 diabetes etc.), may be treated. Treatment for testosterone deficiency with a novel and potentially safer intervention is vital to improve overall health of men.
For more details and to join the campaign, visit: https://netcapital.com/companies/acesis.
Costas N. Karatzas, M.Sc., Ph.D.
Co-founder & CEO
720-389-0650
information@acesisbio.com
CONTACT: Costas N. Karatzas, M.Sc., Ph.D.
Co-founder & CEO
720-389-0650
information at acesisbio.com
